Monro, Inc. (Nasdaq: MNRO) has released its financial results for the fourth quarter of fiscal 2023, reporting adjusted earnings per share (EPS) that fell short of market expectations. The company's adjusted EPS for the quarter stood at $0.08, compared to the consensus estimate of $0.31. 

$MNRO is currently trading at $47.00 in pre-market, experiencing a decline of $1.93 (-3.94%).

In other news, Micron Technology, Inc. (Nasdaq: MU) has made an exciting announcement regarding its plans to introduce extreme ultraviolet (EUV) technology in Japan. The company will leverage this advanced patterning technology to produce its next generation of DRAM, specifically targeting the 1-gamma (1γ) node. Micron is set to become the first semiconductor company to implement EUV technology for production in Japan. 

In pre-market trading, $MU is performing well, currently trading at $65.79, with a gain of $0.87 (+1.34%).

Mullen Automotive, Inc. (Nasdaq: MULN) has shared significant news about its common stock trading above $1 for ten consecutive business days, which positions the company for continued listing on Nasdaq. MULN now awaits confirmation from Nasdaq regarding its compliance with the exchange's requirements. 

In pre-market trading, $MULN is showing positive movement, currently trading at $1.26, with a gain of $0.03 (+2.4390%).

Additionally, FibroGen, Inc. (Nasdaq: FGEN) and its subsidiary, FibroGen (China) Medical Technology Development Co., Ltd., have announced encouraging topline data from their Phase 3 clinical study of roxadustat. The study focused on treating anemia in patients receiving concurrent chemotherapy for non-myeloid malignancies in China. Notably, the Phase 3 clinical study met the primary endpoint of demonstrating the noninferiority of roxadustat to erythropoietin alfa. 

Following this announcement, $FGEN is performing well in pre-market trading, currently trading at $18.35, with a gain of $0.53 (+2.97%).

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)